Phase II Study of Forodesine in Subjects With Chronic Lymphocytic Leukemia (CLL)

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

March 31, 2008

Primary Completion Date

November 30, 2010

Study Completion Date

November 30, 2011

Conditions
Chronic Lymphocytic Leukemia (CLL)
Interventions
DRUG

forodesine HCl

2 x 100mg capsules daily

Trial Locations (11)

3144

Cabrini Hospital, Malvern

3199

Frankston Hospital, Frankston

4029

Royal Brisbane and Women's Hospital, Brisbane

10065

Weill Cornell Medical College, New York

14263

Roswell Park Cancer Institute, Buffalo

20817

Center for Cancer & Blood Disorders, PC, Bethesda

46202

Indiana University Cancer Pavillion, Indianapolis

63110

Washington University School of Medicine, St Louis

90095

UCLA Medical Center, Los Angeles

90211

Tower Cancer Research Foundation, Beverly Hills

97239

Oregon Health & Science University, Portland

Sponsors
All Listed Sponsors
lead

BioCryst Pharmaceuticals

INDUSTRY